DOTA-RGDV，DOTA偶聯(lián)多肽RGDV

名稱：DOTA-RGDV，DOTA偶聯(lián)多肽RGDV

Studies using a baboon model showed that RGDV selectively inhibits platelet-dependent thrombus formation in vivo. In a study by Kawahara et al. on the inhibitory effects of adhesion oligopeptides on the invasion of squamous carcinoma cells RGDV was the most effective inhibitor amongst the evaluated peptides.

RGDV 是一種四肽，可將附著的化合物遞送至血栓或腫瘤細(xì)胞等靶點(diǎn)，它增強(qiáng)了***和抗聚集或抗粘連化合物的功效。 RDGV 結(jié)合細(xì)胞表面的整合素并防止纖維蛋白原與血小板結(jié)合。

RGDV is a tetrapeptide that delivers attached compounds to targets such as thrombus or tumor cells; it enhances efficacy of anticancer and anti-aggregation or anti-adhesion compounds. RDGV binds integrins on the surfaces of cells and prevents binding of fibrinogen to platelets.

中文名稱：RGDV

英文名：RGDV

CAS號(hào)：93674-99-8

單字母：H2N-RGDV-OH

三字母：H2N-Arg-Gly-Asp-Val-COOH

氨基酸個(gè)數(shù)：4

分子式：C17H31N7O7

平均分子量：445.47

***分子量：445.23

等電點(diǎn)(PI)：6.34

pH=7.0時(shí)的凈電荷數(shù)：-0.02

平均親水性：1.5

疏水性值：-1.05

來源：Synthetic

純度：95%、98%

鹽體系：可選TFA、HAc、HCl或其它

生成周期：2-3周

儲(chǔ)存條件：-20 ± 5 °C

相關(guān)試劑列表：

DOTA-(CONH2)3      913528-04-8

DOTA-(COOt-Bu)3      137076-54-1

DOTA-(COOt-Bu)3-azide      1402795-92-9

DOTA-(COOt-Bu)3-butyne      2125661-54-1

DOTA-(COOt-Bu)3-C2-NH2      173308-19-5

DOTA-(COOt-Bu)3-C4-NH2      1402393-59-2

DOTA-(COOt-Bu)3-Mal      1613382-10-7

DOTA-(COOt-Bu)3-NHFmoc-Lys      479081-06-6

DOTA mono-NHS ester      170908-81-3

DOTA-(COOt-Bu)3-NHS      819869-77-7